Last edition
News about "oral orexin 2 receptor"
Lundbeck's Oral Narcolepsy Drug Candidate Receives FDA Fast Track Designation
Lundbeck has received FDA Fast Track designation for Lu AH69593, its investigational oral orexin 2 receptor agonist, accelerating the development of a potential new treatment for patients living with narcolepsy.
Oral Orexin 2 Receptor | 27/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members